

# Susanna V Ulahannan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5857723/publications.pdf>

Version: 2024-02-01

25  
papers

1,241  
citations

932766

10  
h-index

996533

15  
g-index

26  
all docs

26  
docs citations

26  
times ranked

2229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2017, 66, 545-551.	1.8	624
2	Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. <i>Cancer</i> , 2016, 122, 1757-1765.	2.0	245
3	Earlier presentation and application of curative treatments in hepatocellular carcinoma. <i>Hepatology</i> , 2014, 60, 1637-1644.	3.6	78
4	Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. <i>Cancer Investigation</i> , 2011, 29, 325-337.	0.6	66
5	Modulation of tumor eIF4E by antisense inhibition: A phase I/II translational clinical trial of ISIS 183750, an antisense oligonucleotide against eIF4E, in combination with irinotecan in solid tumors and irinotecan-refractory colorectal cancer. <i>International Journal of Cancer</i> , 2016, 139, 1648-1657.	2.3	55
6	Pancreatic Squamous Cell Carcinoma. <i>Pancreas</i> , 2016, 45, 1432-1437.	0.5	43
7	A phase II study of TRC105 in patients with hepatocellular carcinoma who have progressed on sorafenib. <i>United European Gastroenterology Journal</i> , 2015, 3, 453-461.	1.6	36
8	A Phase 1a/b Open-Label, Dose-Escalation Study of Etigilimab Alone or in Combination with Nivolumab in Patients with Locally Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 882-892.	3.2	29
9	Preclinical Evaluation and Phase Ib Study of Prexasertib, a CHK1 Inhibitor, and Samotolisib (LY3023414), a Dual PI3K/mTOR Inhibitor. <i>Clinical Cancer Research</i> , 2021, 27, 1864-1874.	3.2	20
10	A Phase 1, Open-Label Study of MGD013, a Bispecific DART <sup>®</sup> Molecule Binding PD-1 and LAG-3 in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 21-22.	0.6	13
11	Identification of active chemotherapy regimens in advanced biliary tract carcinoma: a review of chemotherapy trials in the past two decades. <i>Hepatic Oncology</i> , 2015, 2, 39-50.	4.2	10
12	A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer. <i>Targeted Oncology</i> , 2021, 16, 569-589.	1.7	10
13	Reversible HER2 antibody-drug conjugate-induced ocular toxicity. <i>Canadian Journal of Ophthalmology</i> , 2021, , .	0.4	7
14	Hepatocellular carcinoma and immune therapy, from a clinical perspective; where are we?. <i>Hepatic Oncology</i> , 2016, 3, 183-185.	4.2	2
15	Phase I/II study of ISIS 183750 in combination with irinotecan for advanced solid tumors or colorectal cancer: Final results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 639-639.	0.8	2
16	Pancreatic squamous cell carcinoma: Epidemiology, clinicopathologic characteristics, and outcomes.. <i>Journal of Clinical Oncology</i> , 2016, 34, 220-220.	0.8	1
17	Paired tumor biopsy analysis and safety data from a pilot study evaluating Tremelimumab - a monoclonal antibody against CTLA-4 - in combination with ablative therapy in patients with hepatocellular carcinoma (HCC). , 2014, 2, .		0
18	VEGF. , 2017, , 537-543.		0

#	ARTICLE	IF	CITATIONS
19	TRC105 for the treatment of hepatocellular carcinoma: Preclinical data and preliminary results from two clinical trials evaluating monotherapy and combination with sorafenib.. Journal of Clinical Oncology, 2014, 32, 211-211.	0.8	0
20	Disconnect between earlier presentation patterns and application of curative treatments in HCC.. Journal of Clinical Oncology, 2014, 32, 187-187.	0.8	0
21	Curative treatments and survival benefit in elderly patients with hepatocellular carcinoma: A SEER population-based analysis.. Journal of Clinical Oncology, 2015, 33, 355-355.	0.8	0
22	A phase I/II study of TRC105 in combination with sorafenib in hepatocellular carcinoma (HCC).. Journal of Clinical Oncology, 2015, 33, 291-291.	0.8	0
23	Abstract 875: Risk factors for hepatocellular carcinoma (HCC) by race/ ethnicity in the United States. , 2015, , .		0
24	Abstract 3421: Epidemiology and survival in patients with extragastric signet ring carcinoma. , 2016, , .		0
25	Abstract 5015: Pretreatment carcinoembryonic antigen levels predict survival in patients with rectal adenocarcinoma. , 2016, , .		0